Inflammation that lasts a long time CIDP (cerebral demyelinating polyneuropathy) is an uncommon neurological condition that results in paralysis (impairment of sensory function in limbs). The ...

CARLSBAD, Calif., Dec. 21, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved Ionis and AstraZeneca's ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Amvuttra, an RNA interference therapeutic for the treatment of polyneuropathy of hereditary ...

This report provides a detailed analysis of the peripheral neuropathy treatment market by type (diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, and others) and geography ...

LONDON--(BUSINESS WIRE)--The peripheral neuropathy treatment market is poised to grow by USD 241.99 million during 2020-2024 progressing at a CAGR of almost 3% during the forecast period. Worried ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has granted ...

PHOENIX, Arizona — In the difficult challenge of treating peripheral neuropathy, a novel approach combining injections of local anesthesia with electronic signal treatment shows improved efficacy in ...

StemWave acoustic wave therapy offers a non-invasive alternative to traditional peripheral neuropathy treatments, with clinical data from Mercy Family Health showing approximately 85% of patients ...

New York, USA, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Chemotherapy-induced Peripheral Neuropathy Treatment Market Poised for Strong Growth Throughout the Forecast Period (2025–2034) Amid Rising ...

Peripheral Neuropathy in its simplest definition is damage to the peripheral nerves — nerves located outside the brain and spinal cord. It is a relatively common condition that is not isolated to any ...

TEGSEDI is first antisense oligonucleotide medicine available to patients in Portugal for at-home subcutaneous injection BOSTON, June 1, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a ...